Cansortium Past Earnings Performance
Past criteria checks 0/6
Cansortium has been growing earnings at an average annual rate of 15.3%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 25.9% per year.
Key information
15.3%
Earnings growth rate
25.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 25.9% |
| Return on equity | -230.1% |
| Net Margin | -12.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cansortium makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 103 | -13 | 36 | 0 |
| 31 Mar 24 | 100 | -20 | 34 | 0 |
| 31 Dec 23 | 97 | -23 | 31 | 0 |
| 30 Sep 23 | 95 | -36 | 29 | 0 |
| 30 Jun 23 | 92 | -36 | 28 | 0 |
| 31 Mar 23 | 90 | -34 | 26 | 0 |
| 31 Dec 22 | 88 | -37 | 26 | 0 |
| 30 Sep 22 | 83 | -15 | 27 | 0 |
| 30 Jun 22 | 76 | -2 | 27 | 0 |
| 31 Mar 22 | 70 | -24 | 27 | 0 |
| 31 Dec 21 | 65 | -19 | 30 | 0 |
| 30 Sep 21 | 62 | -31 | 32 | 0 |
| 30 Jun 21 | 61 | -47 | 33 | 0 |
| 31 Mar 21 | 57 | -28 | 35 | 0 |
| 31 Dec 20 | 52 | -37 | 32 | 0 |
| 30 Sep 20 | 47 | -48 | 35 | 0 |
| 30 Jun 20 | 40 | -51 | 35 | 0 |
| 31 Mar 20 | 33 | -51 | 35 | 0 |
| 31 Dec 19 | 29 | -53 | 41 | 0 |
| 30 Sep 19 | 24 | -54 | 41 | 0 |
| 30 Jun 19 | 19 | -13 | 39 | 0 |
| 31 Mar 19 | 14 | -9 | 33 | 0 |
| 31 Dec 18 | 8 | 0 | 21 | 0 |
| 30 Sep 18 | 3 | 16 | 14 | 0 |
| 30 Jun 18 | 0 | -15 | 9 | 0 |
| 31 Mar 18 | 0 | -16 | 8 | 0 |
| 31 Dec 17 | 0 | -10 | 8 | 0 |
Quality Earnings: 2WM is currently unprofitable.
Growing Profit Margin: 2WM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2WM is unprofitable, but has reduced losses over the past 5 years at a rate of 15.3% per year.
Accelerating Growth: Unable to compare 2WM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2WM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 2WM has a negative Return on Equity (-230.12%), as it is currently unprofitable.